SpyGlass Pharma, Inc. — Form SCHEDULE 13D/A
Filed November 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Vensana Capital I GP, LLC filed an amended Schedule 13D/A regarding beneficial ownership of SpyGlass Pharma, Inc. The specific amendments to shareholdings, percentages, or acquisition details are not disclosed in the header metadata provided. The filing date is 2026-11-18.
Why this rating
Amendment to 13D disclosure without material dollar amounts or ownership % changes visible in excerpt; routine regulatory update unless core ownership shift materially changed.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.